

CTAGE2 (E-16): sc-68039

BACKGROUND

Cutaneous T cell lymphomas (CTCL) represent a group of malignancies that originate from CD4-T lymphocytes and manifest on the skin. CTCL is a general term for several neoplasms including mycosis fungoides, T cell leukemia/lymphoma and pagetoid reticulosis, all of which are very difficult to treat in the advanced stages. CTAGE2 (cutaneous T cell lymphoma associated-antigen 2) is a member of the cancer/testis antigen family of proteins (CTAGE) that, under normal conditions, are found primarily in the testis with little or no expression in other parts of the body. CTAGE2 is a 754 amino acid protein that shares similarity with CTAGE1 but, unlike CTAGE1, is not found in tumors. CTAGE2 has two known isoforms and is the longer variant of CTAGE1.

REFERENCES

1. Eichmüller, S., Usener, D., Dummer, R., Stein, A., Thiel, D. and Schadendorf, D. 2001. Serological detection of cutaneous T cell lymphoma-associated antigens. *Proc. Natl. Acad. Sci. USA* 98: 629-634.
2. Eichmüller, S. 2002. Towards defining specific antigens for cutaneous lymphomas. *Onkologie* 25: 448-454.
3. Eichmüller, S., Usener, D., Thiel, D. and Schadendorf, D. 2003. Tumor specific antigens in cutaneous T cell lymphoma: expression and sero reactivity. *Int. J. Cancer* 104: 482-487.
4. Usener, D., Schadendorf, D., Koch, J., Dübel, S. and Eichmüller, S. 2003. cTAGE: a cutaneous T cell lymphoma associated antigen family with tumor-specific splicing. *J. Invest. Dermatol.* 121: 198-206.
5. Atanackovic, D., Blum, I., Cao, Y., Wenzel, S., Bartels, K., Faltz, C., Hossfeld, D.K., Hegewisch-Becker, S., Bokemeyer, C. and Leuwer, R. 2006. Expression of cancer/testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma. *Cancer Biol. Ther.* 5: 1218-1225.
6. Costa, F.F., Le Blanc, K. and Brodin, B. 2007. Concise review: cancer/testis antigens, stem cells, and cancer. *Stem Cells* 25: 707-711.

CHROMOSOMAL LOCATION

Genetic locus: CTAGE1 (human) mapping to 18p11.2.

SOURCE

CTAGE2 (E-16) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of CTAGE2 of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-68039 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

APPLICATIONS

CTAGE2 (E-16) is recommended for detection of protein CTAGE2 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).


Suitable for use as control antibody for CTAGE2 siRNA (h): sc-62162, CTAGE2 shRNA Plasmid (h): sc-62162-SH and CTAGE2 shRNA (h) Lentiviral Particles: sc-62162-V.

Molecular Weight of CTAGE2: 86 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

DATA



CTAGE2 (E-16): sc-68039. Immunofluorescence staining of formalin-fixed Hep G2 cells showing membrane localization.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.



Try **CTAGE2/5 (B-1): sc-365330**, our highly recommended monoclonal alternative to CTAGE2 (E-16).